JPWO2021148615A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021148615A5 JPWO2021148615A5 JP2022540729A JP2022540729A JPWO2021148615A5 JP WO2021148615 A5 JPWO2021148615 A5 JP WO2021148615A5 JP 2022540729 A JP2022540729 A JP 2022540729A JP 2022540729 A JP2022540729 A JP 2022540729A JP WO2021148615 A5 JPWO2021148615 A5 JP WO2021148615A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- genetically modified
- lacto
- modified cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 230000001105 regulatory effect Effects 0.000 claims 8
- 229920001542 oligosaccharide Polymers 0.000 claims 5
- 150000002482 oligosaccharides Chemical class 0.000 claims 5
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims 4
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims 4
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims 4
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims 3
- -1 D FL Chemical compound 0.000 claims 3
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims 2
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims 2
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 claims 2
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 claims 2
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 claims 2
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims 2
- IEQCXFNWPAHHQR-YKLSGRGUSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O IEQCXFNWPAHHQR-YKLSGRGUSA-N 0.000 claims 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 claims 2
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims 2
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims 1
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims 1
- 229940062827 2'-fucosyllactose Drugs 0.000 claims 1
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims 1
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 claims 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 claims 1
- UTVHXMGRNOOVTB-IXBJWXGWSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UTVHXMGRNOOVTB-IXBJWXGWSA-N 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 229930193965 lacto-N-fucopentaose Natural products 0.000 claims 1
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 claims 1
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 claims 1
- WMYQZGAEYLPOSX-JOEMMLBASA-N lex-lactose Chemical compound OC1[C@@H](O)[C@@H](O)[C@@H](C)O[C@@H]1O[C@H]1C(O[C@H]2[C@@H](C(O)C(O)C(CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](OC(C(O)CO)[C@H](O)[C@@H](O)C=O)OC(CO)C2O)O)C1NC(C)=O WMYQZGAEYLPOSX-JOEMMLBASA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA202000085 | 2020-01-23 | ||
| DKPA202000085 | 2020-01-23 | ||
| DKPA202000833 | 2020-07-13 | ||
| DKPA202000833 | 2020-07-13 | ||
| PCT/EP2021/051473 WO2021148615A1 (en) | 2020-01-23 | 2021-01-22 | Hmo production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511527A JP2023511527A (ja) | 2023-03-20 |
| JPWO2021148615A5 true JPWO2021148615A5 (https=) | 2023-09-22 |
| JP2023511527A5 JP2023511527A5 (https=) | 2023-09-22 |
Family
ID=74556858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022540729A Pending JP2023511527A (ja) | 2020-01-23 | 2021-01-22 | Ｈｍｏの産生 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230193335A1 (https=) |
| EP (1) | EP4093749A1 (https=) |
| JP (1) | JP2023511527A (https=) |
| CN (1) | CN114981290B (https=) |
| AU (1) | AU2021209394A1 (https=) |
| BR (1) | BR112022014414A2 (https=) |
| WO (1) | WO2021148615A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK180952B1 (en) * | 2020-12-22 | 2022-08-10 | Glycom As | A dfl-producing strain |
| BR112023014557A2 (pt) | 2021-01-22 | 2023-10-17 | Glycom As | Nova proteína (fred) da superfamília de facilitadores principais (mfs) na produção de hmos sialiado |
| DK181497B1 (en) | 2021-05-17 | 2024-03-12 | Dsm Ip Assets Bv | ENHANCING FORMATION OF THE HMOS LNT AND/OR LNnT BY MODIFYING LACTOSE IMPORT IN THE CELL |
| DK181991B1 (en) | 2021-11-11 | 2025-05-15 | Dsm Ip Assets Bv | Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli |
| US20260028634A1 (en) | 2022-03-02 | 2026-01-29 | Dsm Ip Assets B.V. | New sialyltransferases for in vivo synthesis of 3'sl and 6'sl |
| DK181683B1 (en) | 2022-03-02 | 2024-09-20 | Dsm Ip Assets Bv | Cells exprssing new sialyltransferases for in vivo synthesis of lst-a, methods using same and constructs encoding said sialyltransferases |
| DK181319B1 (en) | 2022-03-02 | 2023-08-10 | Dsm Ip Assets Bv | Genetically engineered cells and methods comprising use of a sialyltransferase for in vivo synthesis of 3’sl |
| US20250290078A1 (en) | 2022-04-29 | 2025-09-18 | Dsm Ip Assets B.V. | Hmo producing microorganism with increased robustness towards glucose gradients |
| DK182075B1 (en) * | 2022-06-13 | 2025-07-02 | Dsm Ip Assets Bv | Genetically engineered cells comprising sigma factor modifications for production of heterologous products and methods for use of same |
| DK181765B1 (en) | 2022-07-15 | 2024-12-04 | Dsm Ip Assets Bv | Cells expressing new fucosyltransferases for in vivo synthesis of lnfp-iii, and methods and uses of same |
| DK181911B1 (en) * | 2022-07-15 | 2025-03-18 | Dsm Ip Assets Bv | GENETICALLY ENGINEERED CELLS COMPRISING A RECOMBINANT NUCLEIC ACID SEQUNCE ENCODING A FUCOSYLTRANSFERASE FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES (HMOs) AND METHODS FOR PRODUCING THE HMOs AND USE OF THE ENZYME |
| EP4577061A1 (en) | 2022-08-25 | 2025-07-02 | DSM IP Assets B.V. | Hybrid method for producing complex hmos |
| WO2024110667A1 (en) | 2022-11-25 | 2024-05-30 | Dsm Ip Assets B.V. | Two-strain system for producing oligosaccharides |
| DK182185B1 (en) * | 2022-12-14 | 2025-10-29 | Dsm Ip Assets Bv | Mutated lacto-n-biosidase,method for making the same and method for synthesizing lacto-n-biose containing carbohydrates |
| CN117867054B (zh) * | 2023-01-09 | 2024-09-27 | 山东恒鲁生物科技有限公司 | 合成hmo的方法 |
| CN120677242A (zh) | 2023-02-24 | 2025-09-19 | 帝斯曼知识产权资产管理有限公司 | 用于体内合成人乳寡糖的产物特异性转运蛋白 |
| DK181822B1 (en) | 2023-06-07 | 2025-01-30 | Dsm Ip Assets Bv | Genetically engineered strains with reduced byproduct formation and methods and uses of same |
| WO2025047865A1 (ja) * | 2023-08-30 | 2025-03-06 | キリンホールディングス株式会社 | 遺伝子改変微生物、及びオリゴ糖の製造方法 |
| WO2025047866A1 (ja) * | 2023-08-30 | 2025-03-06 | キリンホールディングス株式会社 | 遺伝子改変微生物、及びオリゴ糖の製造方法 |
| DK182227B1 (en) | 2023-10-17 | 2025-12-18 | Dsm Ip Assets Bv | Genetically engineered cells comprising new fucosyltransferases for in vivo synthesis of complex fucosylated human milk oligosaccharides mixtures comprising lnfp-vi, methods using the same, and uses of new fucosyltransferases thereof. |
| WO2025190861A1 (en) | 2024-03-11 | 2025-09-18 | Dsm Ip Assets B.V. | Fucosyltransferase mutants with low dfl formation |
| DK202430472A1 (en) | 2024-08-19 | 2026-02-24 | Dsm Ip Assets Bv | Alpha-1,2 fucosyltransferase mutants with increased alpha 1,3-fucosyltransferase activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2440661T3 (en) * | 2009-06-08 | 2018-03-12 | Jennewein Biotechnologie Gmbh | HMO synthesis |
| EP2675899A4 (en) | 2011-02-16 | 2014-09-10 | Glycosyn LLC | BIOSYNTHESIS OF HUMAN MILK OLIGOSACCHARIDES IN MANIPULATED BACTERIA |
| DE202015009782U1 (de) | 2014-06-11 | 2020-02-10 | Glycom A/S | Trennung von 2'-O-Fucosyllactose aus Fermentationsbrühe |
| EP3191499A4 (en) | 2014-09-09 | 2018-06-06 | Glycosyn LLC | Alpha (1,3) fucosyltransferases for use in the production of fucosylated oligosaccharides |
| US10676770B2 (en) | 2014-12-16 | 2020-06-09 | Glycom A/S | Separation of 2′-FL from a fermentation broth |
| EP3141610A1 (en) | 2015-09-12 | 2017-03-15 | Jennewein Biotechnologie GmbH | Production of human milk oligosaccharides in microbial hosts with engineered import / export |
| DE202017007249U1 (de) | 2016-03-07 | 2020-04-23 | Glycom A/S | Abtrennung von Oligosacchariden aus der Fermentationsbrühe |
| EP4674526A3 (en) | 2016-04-19 | 2026-04-01 | Glycom A/S | Separation of oligosaccharides from fermentation broth |
| ES2856749T3 (es) | 2016-10-29 | 2021-09-28 | Chr Hansen Hmo Gmbh | Proceso para la producción de oligosacáridos fucosilados |
| US11608504B2 (en) * | 2017-12-21 | 2023-03-21 | Glycom A/S | Nucleic acid construct for in vitro and in vivo gene expression |
| US20190323053A1 (en) | 2018-04-23 | 2019-10-24 | Dupont Nutrition Biosciences Aps | Increasing activity of 2? fucosyllactose transporters endogenous to microbial cells |
| US20190323052A1 (en) | 2018-04-23 | 2019-10-24 | Dupont Nutrition Biosciences Aps | Increasing export of 2? fucosyllactose from microbial cells through the expression of a heterologous nucleic acid |
-
2021
- 2021-01-22 JP JP2022540729A patent/JP2023511527A/ja active Pending
- 2021-01-22 AU AU2021209394A patent/AU2021209394A1/en not_active Abandoned
- 2021-01-22 EP EP21703603.7A patent/EP4093749A1/en active Pending
- 2021-01-22 CN CN202180010201.8A patent/CN114981290B/zh active Active
- 2021-01-22 WO PCT/EP2021/051473 patent/WO2021148615A1/en not_active Ceased
- 2021-01-22 US US17/759,270 patent/US20230193335A1/en active Pending
- 2021-01-22 BR BR112022014414A patent/BR112022014414A2/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021148615A5 (https=) | ||
| JPWO2021148611A5 (https=) | ||
| JPWO2021148614A5 (https=) | ||
| AU2024278250A1 (en) | Compositions and methods of treating Huntington's Disease | |
| RU2764587C2 (ru) | Способы и композиции для лечения хореи гентингтона | |
| JP2019213528A (ja) | 祖先ウイルス配列を予測する方法およびその使用 | |
| JP5823969B2 (ja) | 心臓特異的核酸調節因子ならびにこの方法および使用 | |
| KR20250102136A (ko) | 중추 신경계에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법 | |
| JPWO2021148610A5 (https=) | ||
| JP2025121908A (ja) | 二重グリカン結合ａａｖ２．５ベクターのための方法および組成物 | |
| CN106350541A (zh) | 先天性免疫缺陷基因治疗载体构建方法及其用途 | |
| JP2020517268A (ja) | Ｘｌａ遺伝子療法用の最適化されたレンチウイルスベクター | |
| US20220372519A1 (en) | In vitro assembly of anellovirus capsids enclosing rna | |
| CN107735109A (zh) | cMLCK基因导入 | |
| CN104711240B (zh) | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 | |
| CN115485382A (zh) | X连锁病症的治疗中的AAV介导的MiRNA靶向 | |
| EP4007609A1 (en) | Targeted gene therapy to treat neurological diseases | |
| CN114214360A (zh) | 先天性肌无力小鼠模型、其构建方法及应用 | |
| EP4263828A1 (en) | Cardiomyocyte-derived nucleic acid regulatory elements and methods and use thereof | |
| KR102828335B1 (ko) | Gne 근육병 치료용 aav 기반의 유전자 치료제 | |
| CN117660370B (zh) | 一种重组腺相关病毒、抗炎药物及其在脓毒性脑病治疗中的应用 | |
| CN116926043B (zh) | 一种dCasX蛋白核酸酶、重组载体及其应用 | |
| JP2002523046A5 (https=) | ||
| CN1804041A (zh) | 表达人类核心蛋白聚糖的重组腺相关病毒及其制备方法 | |
| WO2026017126A1 (zh) | 一种人工设计的新型nrg-1在疾病治疗中的应用 |